Jazz Pharmaceuticals (JAZZ) Gross Margin (2010 - 2026)
Jazz Pharmaceuticals' (JAZZ) quarterly Gross Margin came in at 87.45% in Q1 2026, down 89.0% year-on-year from 795.04% in Q1 2025, and little changed quarter-over-quarter from 87.18% in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Gross Margin (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Gross Margin history runs 17 years deep, the most recent figure standing at 87.45% for Q1 2026.
- On a quarterly basis, Gross Margin fell 89.0% year-over-year to 87.45% in Q1 2026; TTM through Mar 2026 was 88.0%, a 81.0% decrease from a year earlier, with the FY2025 full-year figure at 88.21%, down 84.0% from the prior year.
- Gross Margin steadied at 87.45% in Q1 2026 per JAZZ's latest filing, from 87.18% in the prior quarter.
- Across five years, Gross Margin topped out at 89.81% in Q2 2023 and bottomed at 82.78% in Q4 2022.
- The 5-year median for Gross Margin is 88.35% (2025), against an average of 87.77%.
- Across the five-year window, Gross Margin slumped 755 bps in 2022 and jumped 662 bps in 2023, its largest moves.
- Year by year, Gross Margin stood at 82.78% in 2022, then gained by 8 bps to 89.4% in 2023, then slipped by 1 bps to 88.17% in 2024, then dropped by 1 bps to 87.18% in 2025, then gained by 0 bps to 87.45% in 2026.
- Per Business Quant, the three latest JAZZ Gross Margin figures stand at 87.45% (Q1 2026), 87.18% (Q4 2025), and 88.56% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Jazz Pharmaceuticals | 15.78 Bn | 13.93 Bn | 934.80 Mn | 87.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 87.45% |
| Dec 31, 2025 | 87.18% |
| Sep 30, 2025 | 88.56% |
| Jun 30, 2025 | 88.88% |
| Mar 31, 2025 | 88.35% |
| Dec 31, 2024 | 88.17% |
| Sep 30, 2024 | 89.42% |
| Jun 30, 2024 | 89.27% |
| Mar 31, 2024 | 89.41% |
| Dec 31, 2023 | 89.40% |
| Sep 30, 2023 | 89.49% |
| Jun 30, 2023 | 89.81% |
| Mar 31, 2023 | 85.59% |
| Dec 31, 2022 | 82.78% |
| Sep 30, 2022 | 85.79% |
| Jun 30, 2022 | 86.69% |
| Mar 31, 2022 | 85.83% |
| Dec 31, 2021 | 84.82% |
| Sep 30, 2021 | 82.67% |
| Jun 30, 2021 | 84.15% |